5 citations
,
March 2015 in “Clinical and Experimental Dermatology” This case report describes a 22-year-old woman who developed persistent, non-scarring hair loss and premature ovarian failure following a myeloablative umbilical cord transplant for acute myeloid leukemia.
September 2025 in “PubMed” In this Delphi study, international experts established consensus-based guidelines for diagnosing and managing persistent chemotherapy-induced alopecia (pCIA), recommending prevention through scalp cooling and early use of minoxidil, while advising against bicalutamide and certain finasterides for breast cancer patients due to safety concerns.
57 citations
,
March 2011 in “The American Journal of Dermatopathology” This study found that permanent alopecia can occur after certain chemotherapy treatments and presents as nonscarring hair loss similar to androgenetic alopecia, with specific histological features that could be misdiagnosed without proper clinicopathological correlation.
19 citations
,
June 2020 in “International Journal of Dermatology” In this systematic review, oral minoxidil was found to be a safe and effective treatment for androgenetic alopecia and alopecia areata, with additional benefits for female pattern hair loss and other types of alopecia, although common side effects included hypertrichosis and postural hypotension.
34 citations
,
January 2018 in “International Journal of Dermatology” This review discusses chemotherapy-induced alopecia, highlighting its pathogenesis, clinical patterns, and current therapeutic approaches, with no new clinical results reported.
